key: cord-0843520-w37q9sgs authors: ARIAN, Mahdieh; VALINEJADI, Ali; VAKILIAN, Farveh title: Comparing of the First Electrocardiographic Variables in Patients with Newly Diagnosed COVID-19 with Healthy Men Volunteer: A Systematic Review and Meta-Analysis date: 2021-01-03 journal: Iran J Public Health DOI: 10.18502/ijph.v50i1.5071 sha: fe39b0c57903a4731f7e508264be141797bbc2ff doc_id: 843520 cord_uid: w37q9sgs BACKGROUND: We aimed to report the findings of the first Electrocardiography (ECG), before therapy initiation and receiving medication in COVID-19 patients, and to compare them with the ECG findings of healthy men. METHODS: A comprehensive and regular search was performed through the keywords (“Electrocardiographic” OR “ECG” OR; “COVID-19” OR “Coronavirus Disease 2019”) without time and language restrictions in the Web of Science, Scopus, ProQuest, Cochrane Library, Science Direct, Medline, PubMed and Google Scholar. After evaluating the quality and reviewing the biases, 27 studies were finally enrolled. RESULTS: In 27 studies with a total number of 3994 COVID-19 patients, and mean age of 62.7 yr, 1993 subjects were male. The most common type of arrhythmia in them, especially in severe and critical cases, was 7% based on 10 studies (Atrial Fibrillation); while in 7 studies, QTc interval prolong (≥ 460 msec) was 15% and in 5 studies, QTc interval prolong (≥ 500 msec) was 18%. In COVID-19 patients at the time of admission and healthy men, HR (b per / min) was 85, 61.7 and PR interval (msec) was 285.4, 156 and QRS duration (msec) was 95, 94.3 and QT (msec) was 380. 384.1 and QTc (msec) (Bazett’s formula) was 437, 387.1, respectively. In most cases, the variables were higher for COVID-19 patients. CONCLUSION: ECG abnormalities at the time of admission and prior to the initiation of medication that cause arrhythmic may have a clinically substantial effect on the course of the disease and confirm the effect of COVID-19 on increased cardiovascular risk in long-term. Coronavirus Disease 2019 (COVID-19) is a clinical manifestation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) with a high mortality rate. The clinical course of the infection is characterized by respiratory symptoms including fever, cough, and fatigue, and may progress to pneumonia, Acute Respiratory Distress Syndrome (ARDS), and shock (1) . Adverse effects of COVID-19 on cardiovascular disease with acute cardiovascular syndrome have been described as decompensated heart failure, acute coronary syndromes and myocarditis, which increase mortality (2) . Therefore, it is important to identify prognosisrelated markers that assist physicians in rapidly triaging and conduct clinical decision-making. Electrocardiography (ECG) is a fully accessible diagnostic test performed quickly without large numbers of personnel being exposed to SARSCoV2. ECG has been shown to increase prognostic value in population-based studies and among patients with a variety of underlying cardiovascular diseases, including hypertension (3) . Therefore, it is of special seriousness during the current epidemic. Therefore, the objective of the present systematic review and meta-analysis was to report the findings of the first ECG, before starting treatment and prior to receiving medication in Covid-19 patients, and to compare them with the ECG findings of healthy men. The objective of the present meta-analysis is to report the findings of the first ECG, prior to treatment initiation and before receiving medication in COVID-19 patients, and to compare them with the ECG findings of healthy men. The present study was conducted based on the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) (4) and it has the ethics code (IR.SEMUMS.REC.1399.230). Components of structured question (PICO) were population (P): newly diagnosed patients with COVID-19; and intervention (I): not required; comparison (C): with healthy men; outcome (O): findings of the first ECG before treatment initiation and receiving medication. The results of this meta-analysis in COVD-19 patients were compared to the results of the study in healthy men volunteer (5) . A comprehensive and regular search was performed with the keywords ("Electrocardiographic" OR "ECG" OR; ''COVID-19'' OR ''Corona-virus Disease 2019'') without time and language restrictions in the following databases: Web of Science, Scopus, ProQuest, Cochrane Library, Science Direct, Medline, PubMed and Google Scholar. Retrospective, prospective, randomized, and nationwide studies reported the first ECG findings of COVID-19 patients before receiving any medication were included in this review; and pediatric studies or studies that did not report the findings of the first ECG prior to treatment in these patients, and case report studies were excluded. Out of 589 searches, 149 were excluded due to duplication. Title and abstract of 440 studies were reviewed. Texts that did not contain ECG or COVID-19 related findings in their titles and abstracts were also excluded in 358 cases. Eightytwo full-text articles were reviewed by two researchers based on inclusion and exclusion criteria. Fifty articles were excluded due to lack of detailed reporting of ECG findings and five were excluded due to ECG findings reported after receiving medication. Finally, 27 articles were selected and included in quality evaluation stage ( Fig. 1 ). To evaluate the critical evaluation of studies, a 5item checklist was used based on JBI Critical Appraisal Checklist for Case Control Studies and longitudinal cohort, or cross-sectional Studies Reporting Prevalence Data (6) . The two authors independently reviewed each study based on the criteria in these checklists with the options of "Yes", "No", and "Unclear". For each item "Yes", had a score of two, "Unclear" had a score of one and "No" had no score. Total scores of each study were considered as total scores. Quality classification of studies in this 5-item checklist was high (7-10), Moderate (3) (4) (5) (6) , and Weak (3>). Figure 2 shows a review of the biases of the reported studies. Available at: http://ijph.tums.ac.ir Based on the inclusion and exclusion criteria, the two researchers independently reviewed the title and abstract of the studies. Whenever there was disagreement between them in selecting the articles, the third person, as a judge, resolved the disagreement through discourse. Variables were extracted from the study, including the name of the first author, publication year, age, sample size, BMI, and findings of the first ECG at the time of admission and prior to drug administration. Mean or Prevalence was reported by confidence interval (95% CI). Besides, the randomized model was reported by 95% CI. P value < 0.05 was considered statistically significant. The Q statistic and the I 2 index were used to assess the heterogeneity of the studies. The I 2 index was used due to its accuracy to compensate for the lack of power (the Q statistic) in small sample sizes or increase the power in large sample sizes. In the I 2 index, a value of less than 50% indicated low var-iance between studies and a fixed effect model and the inverse variance method were used. Otherwise I-V heterogeneity method was used (7) . Studies data were entered into comprehensive meta-analysis and -5RecMan softwares and data were analyzed. The radar chart was used to compare the ECG findings of COVID-19 patients and healthy men. In 27 studies published in 2020, a total of 3994 COVID-19 patients were studied, of which 1993 were male. Figure 3 depicts the details of pooled mean scores and graphical funnel plot for QTc (msec) based on Bazett's formula in COVID-19 patients before therapy initiation. The radar chart (Fig. 4) compares the findings of the first ECG of COVID-19 patients before therapy initiation with the findings of a meta-analysis related to the ECG findings of healthy male volunteers before receiving any intervention. The most changes were related to PR interval (msec), QTc (msec) (Bazett's formula) and HR (b per / min). In two studies, there was no significant difference between the survived and died groups in the standardized mean QTc (msec) (P = 0.36) with 95% CI of -0.30, 0.11. In three studies, there was no significant difference between the survived and died groups in the standardized mean HR (b per / min) (P = 0.92) with 95% CI of -0.31, 0.27 (Fig. 5-A) . In three case-control studies, there was no significant difference between the control group and COVID-19 group in the standardized mean QTc (msec) (P = 0.08) with 95% CI of -0.09, 1.67 and HR (b per / min) (P = 0.15) with 95% CI of -0.48, 3.06 (Fig. 5-B) . In the present study, publication bias was reported by the Egger test and the results are shown in Table 2 . Moreover, graphical funnel plots were symmetrical in most zones and did not show bias. Funnel plot for QTc (msec) is shown in Fig. 3 . Despite the important role of the ECG in diagnosing the complications of COVID-19 in the acute phase, unfortunately there is no detailed study on the characteristics of the ECG and their changes during the hospitalization of COVID-19 patients before starting pharmacotherapy. In this regard, the researchers of the present study analyzed the data of 27 studies on the findings of the first ECG of COVID-19 patients who were hospitalized and had not yet received medical treatment. Finally, they have provided some of the key issues that are worth mentioning. ECG abnormalities at the time of hospitalization due to COVID-19 entailed a wide range of cardi ovascular complications including acute coronary syndrome, arrhythmic disorders and ST-T ischemic changes, so that based on the data analysis from five studies T inverted was 15% and according to data analysis in seven studies ST-T abnormalities was 22%. Cardiac arrhythmias in COVID-19 patients were similar to those in SARS patients in 2003 (33) . Analysis of five studies showed that Sinus Tachycardia with 34% is the most common type of arrhythmia in COVID-19 patients, especially in severe and critical cases. In ten studies, atrial fibrillation was 7%. Thus, it is possible that atrial fibrillation in COVID-19 is associated with increased systemic inflammation, fever, hypoxia, and adrenergic tone (2) . However, involvement of epicardial adipose tissue during SARS-CoV-2 infection is associated with atrial electrical regeneration and the progression of atrial fibrillation (34) . In four studies, premature beat was 15%. Given the before therapy reviews, the inflammatory response caused by COVID-19 may be more effective on the higher prevalence of premature atrial and ventricular beats than on medications (29) . Altogether, these findings reinforce the recommendation to accurately reassess and evaluate therapy options of anticoagulants, balancing the risk of thromboembolic and bleeding risk. In COVID-19 patients, hydroxychloroquine and azithromycin are at risk for QT prolongation. However, the present study analyzed the ECG findings before starting treatment, according to which in seven studies, QTc interval prolong (≥ 460 msec) was 15% and in five studies, QTc interval prolong (≥ 500 msec) was 18%. Due to the lack of medication use before ECG, QT prolongation may be due to monogenetic stress or other undetected hereditary lesions (35) ; and in several studies, the main reason for the prolongation of QT has been mentioned to be the use of arrhythmogenic drugs. However, since the initial ECG of COVID-19 patient shows a relative QT prolongation, further studies are needed to assess the interval. In some previous studies, the details of the time of diagnosis before hospitalization were not specified, and just the first ECG was recorded at the time of admission for the patients diagnosed with COVID-19. The lack of details of detection time may have led to some details of the treatment not being reported, and patients may have been taking medication before being admitted to the hospital, but this has not been mentioned in the articles. Data analysis showed that in COVID-19 patients at the admission time and in healthy men, HR (b per / min) was 85, 61.7; PR interval (msec) was 285.4, 156; QRS duration (msec) was 95, 94.3; QT (msec) was 380, 384.1; and QTc (msec) (Bazett's formula) was 437, 387.1, respectively. In most cases for COVID-19 patients, the variables were higher, possibly due to changes in autonom-ic tone, cardiopulmonary or peripheral deconditioning, and myocardial injury. Cardiac arrhythmias and ECG changes in COVID-19 patients before treatment compared to healthy men can occur due to myocardial ischemia, heart failure, increased catecholamine exposure, electrolyte disturbances, scar formation, hypoxia, autonomic dysfunction, and inflammation. Re-entry and acquired automaticity may initiate arrhythmogenesis at the cellular level (36) . Systemic inflammation has significant effects on arrhythmogenesis. Systemic inflammation plays a key role in the development of arrhythmias by reducing the arrhythmogenic threshold in patients prone to arrhythmias. In particular, COVID-19 is associated with complete heart block, acute coronary syndromes, myocarditis, decompensated heart failure, and pulmonary embolism. These findings support the notion that ECG abnormalities at the time of admission and prior to the initiation of arrhythmic medication may have a clinically substantial effect on the course of the disease and confirm the effect of COVID-19 on increased cardiovascular risk in long run. Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors. 2019 Novel coronavirus: where we are and what we know Electrocardiographic features of patients with COVID-19 pneumonia Electrocardiographic Findings in Coronavirus Disease-19: Insights on Mortality and Underlying Myocardial Processes Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation A meta-analysis of ECG data from healthy male volunteers: diurnal and intra-subject variability, and implications for planning ECG assessments and statistical analysis in clinical pharmacology studies JBI Manual for Evidence Synthesis Quantifying heterogeneity in a meta-analysis Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China Cardiovascular manifestations in severe and critical patients with COVID -19 Validating QT-Interval Measurement Using the Apple Watch ECG Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin Electrocardiographic Findings of COVID-19 Patients and Their Correlation with Outcome Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA Chloroquine-induced QTc prolongation in COVID-19 patients Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City Clinical, Radiological Features and Outcome of COVID-19 patients in a Secondary Hospital in Jakarta, Indonesia Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection Enhanced electrocardiographic monitoring of patients with Coronavirus Disease The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients Interpretation of arrhythmogenic effects of COVID-19 disease through ECG Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin Cardiovascular complications of severe acute respiratory syndrome Pericardial fat is associated with atrial conduction: the Framingham Heart Study SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes Systemic inflammation and arrhythmogenesis: a review of mechanistic and clinical perspectives Research reported in this publication was supported from the Semnan University of Medical Sciences, Semnan, Iran. The authors declare that there is no conflict of interest.